A new recombinant factor VIII: from genetics to clinical use

from genetics to clinical use".1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, N...

Full description

Saved in:
Bibliographic Details
Published in:Drug design, development and therapy development and therapy, 2015-01, Vol.9, p.3817-3819
Main Authors: Kannicht, Christoph, Kohla, Guido, Tiemeyer, Maya, Walter, Olaf, Sandberg, Helena
Format: Article
Language:English
Subjects:
Animals
Coagulation factors
Factor VIII - genetics
Factor VIII - therapeutic use
Genetics
Hemophilia A - therapy
Humans
Letter
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:from genetics to clinical use".1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq®).2-4 Nuwiq® is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.5 Read the original article
ISSN:1177-8881
1177-8881
DOI:10.2147/DDDT.S85608